Paris, France — 18 June 2023 — Genèse Labs has entered into formal partnerships with Key Opinion Leaders (KOLs) and biotechnology laboratories to develop its next generation of aesthetic products, involving clinicians directly from the formulation stage rather than only in post-launch evaluation.

In aesthetic medicine the gap between laboratory performance and clinical reality is unusually wide. A formulation may exhibit excellent characteristics under controlled conditions yet prove difficult to inject or integrate unpredictably with tissue in practice. Practitioners encounter these discrepancies daily, but their observations rarely reach development teams in any systematic way. By involving KOLs from the earliest stages of formulation design, Genèse Labs was able to treat factors such as handling and post-treatment response as design variables from the outset. The results are visible in the products themselves — the smooth handling that allows Proluma PDLLA to be used by general practitioners, and the uniform injection characteristics that make RG60® suitable for large-volume body treatments.

Parallel partnerships with biotechnology laboratories supplied the technical capability required for the categories the company intended to enter. Polymer-based collagen stimulators, exosome- and PDRN-derived actives, and cross-linked hyaluronic acid each demand different expertise in materials science, particle engineering and biocompatibility assessment. By establishing relationships with laboratories specialising in each field, Genèse Labs was able to advance several technology platforms simultaneously while maintaining rigorous standards in everyone.

The productivity of this model was quickly demonstrated. Within eighteen months of the partnerships being signed, RG60®, Proluma™ PDLLA, Citrus Bottle™ and the Exoluma™ series were launched in succession — each emerging from a process that combined laboratory formulation development with structured clinical feedback, and each designed from the start to meet European regulatory requirements. 

Genèse Labs is a Paris-founded aesthetic company dedicated to science-based, regulatory-led product development across the fast-growing fields of body contouring, collagen biostimulation, and regenerative skincare. Since its foundation in 2019, the company has built its portfolio — including RG60®, Proluma™, Citrus Bottle™ and the Exoluma™ series — on three principles: scientifically verifiable formulations, regulatory compliance in every market entered, and continuous engagement with the international clinical and academic community. Genèse Labs partners with dermatologists, aesthetic physicians, and distributors worldwide to advance the standard of modern aesthetic medicine. For more information: www.geneselabs.net.